A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial

George Salaminios (Lead / Corresponding author), Larisa Duffy, Anthony Ades, Ricardo Araya, Katherine S. Button, Rachel Churchill, Timothy Croudace, Catherine Derrick, Padraig Dixon, Christopher Dowrick, Simon Gilbody, William Hollingworth, Vivien Jones, Tony Kendrick, David Kessler, Daphne Kounali, Paul Lanham, Alice Malpass, Tim J. Peters, Derek RiozzieJude Robinson, Debbie Sharp, Laura Thomas, Nicky J. Welton, Nicola Wiles, Glyn Lewis

Research output: Contribution to journalArticle

5 Citations (Scopus)
137 Downloads (Pure)

Abstract

Background: Depressive symptoms are usually managed within primary care and antidepressant medication constitutes the first-line treatment. It remains unclear at present which people are more likely to benefit from antidepressant medication. This paper describes the protocol for a randomised controlled trial (PANDA) to investigate the severity and duration of depressive symptoms that are associated with a clinically significant response to sertraline compared to placebo, in people presenting to primary care with depression.

Methods/design: PANDA is a randomised, double blind, placebo controlled trial in which participants are individually randomised to sertraline or placebo. Eligible participants are those who are between the ages of 18 to 74; have presented to primary care with depression or low mood during the past 2 years; have not received antidepressant or anti-anxiety medication in the 8 weeks prior to enrolment in the trial and there is clinical equipoise about the benefits of selective serotonin reuptake inhibitor (SSRI) medication. Participants who consent to participate in the trial are randomised to receive either sertraline or matching placebo, starting at 50mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150mg if required). Participants, general practitioners (GPs) and the research team will be blind to treatment allocation. The primary outcome will be depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9) at 6 weeks post randomisation, measured as a continuous outcome. Secondary outcomes include depressive symptoms measured with the PHQ-9 at 2 and 12 weeks as a continuous outcome and at 2, 6 and 12 weeks as a binary outcome; follow-up scores on depressive symptoms measured with the Beck Depression Inventory-II, anxiety symptoms measured by the Generalized Anxiety Disorder-7 and quality of life measured with the Euroqol-5D-5L and Short Form-12; emotional processing task scores measured at baseline, 2 and 6 weeks; and costs associated with healthcare use, time off work and personal costs.

Discussion: The PANDA trial uses a simple self-administered measure to establish the severity and duration of depressive symptoms associated with a clinically significant response to sertraline. The evidence from the trial will inform primary care prescribing practice by identifying which patients are more likely to benefit from antidepressants.
Original languageEnglish
Article number496
Pages (from-to)1-14
Number of pages14
JournalTrials
Volume18
DOIs
Publication statusPublished - 24 Oct 2017

    Fingerprint

Keywords

  • Depression
  • Primary care
  • Antidepressants
  • Sertraline
  • Selective Serotonin reuptake inhibitors

Cite this

Salaminios, G., Duffy, L., Ades, A., Araya, R., Button, K. S., Churchill, R., Croudace, T., Derrick, C., Dixon, P., Dowrick, C., Gilbody, S., Hollingworth, W., Jones, V., Kendrick, T., Kessler, D., Kounali, D., Lanham, P., Malpass, A., Peters, T. J., ... Lewis, G. (2017). A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. Trials, 18, 1-14. [496]. https://doi.org/10.1186/s13063-017-2253-4